Form 4: Abbott Laboratories Executive Vice President Hubert L. Allen Reports Stock Transactions

Executive Vice President of Abbott Laboratories, Hubert L. Allen, exercised stock options and sold shares on January 29th and 30th, 2025.

Summary

• Hubert L. Allen, an Executive Vice President at Abbott Laboratories, engaged in multiple transactions involving the company's stock.
• On January 29, 2025, Allen exercised options to acquire 131,360 common shares at a price of $38.40 per share and then sold the same amount of shares at a weighted average price of $128.3471.
• On January 30, 2025, Allen exercised options to acquire 58,428 common shares at a price of $38.40 per share and then sold the same amount of shares at a weighted average price of $128.0658.
• The sales were executed in multiple transactions with prices ranging from $127.90 to $128.81 on January 29th and $128.00 to $128.40 on January 30th.
• Following these transactions, Allen's direct holdings of Abbott Laboratories common stock decreased by the amount of shares sold.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself.

Industry Context

This is a routine filing related to stock transactions by a company executive, which is common practice in publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and are required by the SEC to ensure transparency of insider trading.
• The transactions are typical for executives who receive stock options as part of their compensation package.
• The prices at which the shares were sold are within the normal trading range for Abbott Laboratories stock.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
• The transactions are part of the executive's compensation and do not indicate any change in the company's performance or outlook.

Key Dates

Keywords

Abbott Laboratories, stock options, insider trading, executive compensation, stock sales, Form 4, equity securities